Isomorphic Labs

Investor: Thrive Capital

London-based Isomorphic Labs, the AI-first drug discovery company spun out of Google DeepMind, has secured a historic £1.6 billion ($2.1 billion) Series B funding round led by Thrive Capital. Summary of transaction details: Value: £1.6 billion ($2.1 billion) Sector: Healthcare & Biotech / MedTech Advisor: Not disclosed Key Entities: Target: Isomorphic Labs; Lead Investor: Thrive Capital; Participating Investors: Alphabet, GV, MGX, Temasek, CapitalG, and the UK Sovereign AI Fund Location: London, UK Note: Founded by Sir Demis Hassabis, Isomorphic Labs is on a mission to "solve all disease" by transitioning from pioneering AI models to applying them at industrial scale. This capital injection focuses on the deployment of IsoDDE, the firm's proprietary AI drug design engine. The platform has already hit key milestones across internal programs with "unprecedented speed" and supports major strategic partnerships with industry titans including Novartis, Eli Lilly, and Johnson & Johnson. The funding follows a £462.3 million raise in April 2025 and will be used to accelerate therapeutic pipelines toward clinical trials while scaling global hiring for AI, engineering, and clinical talent.

Investor: Thrive Capital

Isomorphic Labs, a prominent spinout from Google DeepMind specializing in AI-driven drug discovery technology, has successfully secured $600 million (£464.6 million) in its inaugural external funding round.Summary of transaction details:Value: £464.6 millionSector: Healthcare & Biotech, DeepTech & AIAdvisor: None mentionedKey Entities: Target: Isomorphic Labs; Lead Investor: Thrive Capital; Additional Investors: Alphabet, Google VenturesLocation: UK-affiliatedNote: This substantial investment underscores the increasing strategic importance and high growth potential of artificial intelligence applications in revolutionizing pharmaceutical research and development, positioning Isomorphic Labs as a key player in the future of drug design.

Investor: Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund

Isomorphic Labs, a London-based company leveraging artificial intelligence for drug discovery, has successfully closed a Series B funding round, raising £1.6 billion.Summary of transaction details:Value: £1.6 billionSector: Healthcare & BiotechAdvisor: Not specifiedKey Entities: Isomorphic Labs (Target), Thrive Capital, Alphabet, GV, MGX, Temasek, CapitalG, UK Sovereign AI Fund (Investors)Location: London (Target HQ)Note: This substantial investment underscores the increasing strategic importance and commercial viability of AI applications in accelerating and enhancing the drug discovery process within the pharmaceutical industry.